Blood pressure drug could prevent 60 per cent of type 1 diabetes cases, say researchers

A drug usually related to treating excessive blood pressure could assist prevent type 1 diabetes in 60% of at-risk individuals, researchers have mentioned.

Methyldopa has been round for greater than 50 years and is commonly given to pregnant ladies and kids with excessive blood pressure, however now it’s believed it could produce other makes use of.

Researchers say they’ve discovered proof that it could be helpful within the prevention of type 1 diabetes as a result of the drug can block the DQ8 molecule, present in round 60% of individuals at excessive threat of growing type 1 diabetes.

Professor Aaron Michels, a researcher on the Barbara Davis Center for childhood diabetes and affiliate professor of medication on the University of Colorado Anschutz Medical Campus, mentioned: “With this drug, we can potentially prevent up to 60% of type 1 diabetes in those at risk for the disease. This is a very significant development.”

The group spent 10 years learning the oral drug, usually taken between two and 3 times a day, and what impact it had on mice and 20 individuals with type 1 diabetes.

Prof Michels mentioned: “We can now predict with almost 100 per cent accuracy who is likely to get type 1 diabetes. The goal with this drug is to delay or prevent the onset of the disease among those at risk.”

Fellow researcher David Ostrov, PhD, hopes their methyldopa discovery may assist block different molecules which could imply stopping different illnesses.

Professor Ostrov, affiliate professor on the University of Florida College of Medicine’s Center for NeuroGenetics, mentioned: “This study has significant implications for treatment of diabetes and also other autoimmune diseases [and] suggests that the same approach may be adapted to prevent autoimmune diseases such as rheumatoid arthritis, coeliac disease, multiple sclerosis, systemic lupus erythematosus and others.”

The findings of the examine have been revealed within the Journal of Clinical Investigation.